Navigation Links
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Date:8/17/2009

by at least 3 points. Notably, the 46% of patients who had received previous treatment for BPH showed an important mean improvement of 5 points, which is only slightly less than the 6 point improvement seen in treatment-naive patients. Maximum uroflow improved by 25%, from 10.3 to 12.5 ml/sec, and also the mean uroflow showed similar improvement.

Juergen Engel, Ph.D., AEterna Zentaris President and CEO stated, "Although the data received for the open-label safety study Z-041 with a nearly 6 point reduction in IPSS are in line with what we had observed in our Phase 2 program, we are disappointed by the failure to achieve the primary endpoint in the efficacy study Z-033. We remain committed to the ongoing Phase 3 program with cetrorelix in BPH and are working towards receiving the results of the second pivotal efficacy study Z-036 in November."

Herbert Lepor, M.D., Professor and Chairman, Department of Urology, at NYU School of Medicine, New York and Lead Investigator of the Z-033 trial added, "These findings are unexpected in light of the previous Phase 2 experience. Those data and the strength of the safety data available to date had given us confidence in this potential new treatment for BPH. It is now important to await results of the other placebo-controlled efficacy study Z-036."

Conference Call

The Company will host a conference call and webcast to discuss these results later today, Monday, August 17, 2009 at 10:00 a.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: (outside Canada): 800-588-4942. (Canada): 416-644-3426 or 514-807-8791. A replay of the webcast will also be available on the Company's website for a period of 30 days.

About the Phase 3 Program with Cetrorelix in BPH


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
2. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
3. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
6. AEterna Zentaris Receives US$10 Million from Institutional Investors
7. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
8. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
10. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
11. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... (PRWEB) May 21, 2013 Alpha ... distributor , will be exhibiting for the 13th ... of Medical Instrumentation (AAMI) 2013 Conference and Expo. ... support, distribute, and manufacture healthcare technologies. This year’s ... Long Beach, California. , The three-day event ...
(Date:5/21/2013)... May 21, 2013 Clinverse, ... company for clinical trials, announced today it has ... LLC. Clinverse’s ClinPay® FLS eClinical commerce platform ... process. SpendMD ™, Aggregate Spend Solutions’ ... for tracking and reporting transfer of value at ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 As ... a strong push within the industry to deliver ... Manufacturing Organizations and pharma companies often means turning ... , Microtablets, developed in collaboration with Sensidose AB ... outsourcing can bring products to market sooner. The ...
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... Enterprise-Wide Solutions Designed to Increase Efficiency, ... VTAL ), a leading provider of ... it has released its,next generation enterprise-wide advanced ... of Vitrea(R) 4.0 and ViTALConnect(R) 4.1. This,comprehensive ...
... (Amex:,ADL) announced today that for the three-month period ended ... an approximate increase of 69%,over the first quarter of ... a net loss of ($2,264,305). Included in the loss ... and options issued. Gary Dreher, CEO of AMDL ...
... SAINT LOUIS, Aug. 20 The MattsonJack Group, ... Amit Dhawan M.D.,M.B.A., M.P.H. to Medical Director for ... Dhawan joined MattsonJack in September 2000 as a ... and M.B.A. from the,University of Missouri -- Kansas ...
Cached Biology Technology:Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 2Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 3Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 4AMDL Announces 2nd Quarter 2007 Operational Results 2Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 2Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 3
(Date:5/21/2013)... battle? Try staying fit in space, where living quarters ... , That,s the challenge a group of Michigan State ... million grant from NASA. Their goal is to keep ... "You could give astronauts the best exercise regimen there ... to it, it isn,t going to help," said project ...
(Date:5/21/2013)... insulin action in cells in precise detail like never ... goes wrong in diabetes. , The breakthrough study, ... Sydney,s Garvan Institute of Medical Research, is now published ... Cell Metabolism . , First discovered in 1921, ... the body because it helps us lower blood sugar ...
(Date:5/20/2013)... 20, 2013) University of Minnesota Medical School researchers ... partnership with the University,s Brain Tumor Program, have developed ... tumors (MPNST) that allow them to discover new genes ... The research was published this week in the journal ... transposon method, researchers in the lab of David Largaespada, ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3U of M researchers develop model for better testing, targeting of MPNST 2
... 1, 2011 /PRNewswire-Asia/ -- Clearbridge Accelerator announced today that ... well-established venture capitalist based in the Silicon Valley. Mr ... of Draper Fisher Jurvetson (DFJ), is well known for ... Clearbridge Accelerator is a technology incubator ...
... have access to information critical to understanding the effects ... the National Science Foundation (NSF),s National Ecological Observatory Network ... million observatory with $12.5 million in fiscal year 2011 ... planning. With a construction start in fiscal year ...
... first lab-on-a-chip sensor to provide fast feedback regarding levels of ... environmentally and child friendly, and will first be ... leading a long-term health study on the potential health effects ... to create a sensor that provides fast feedback related to ...
Cached Biology News:Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 2Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 3Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 4Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 6NSF awards construction funding to National Ecological Observatory Network 2New UC sensor promises rapid detection of dangerous heavy metal levels in humans 2New UC sensor promises rapid detection of dangerous heavy metal levels in humans 3
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Request Info...
Request Info...
Request Info...
Biology Products: